TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05381662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells and CD19 positive feeder T cells
Description: Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells and CD19 positive feeder T cells
Description: Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
Study: NCT03974061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Alcohol Intervention
Description: The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
Study: NCT00652834

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Small bowel capsule endoscopy (SBCE)
Description: SBCE will be performed at Day 2 and Day 30.

Intervention type: DRUG
Group type: OTHER
Intervention: myfortic
Description: switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
Study: NCT04037215

Intervention type: OTHER
Group type: OTHER
Intervention: STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE
Description: Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders.
Study: NCT04742023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor Application
Description: The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Finger Stick Glucose Measurement
Description: Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finger Stick Glucose Measurement
Description: Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor Placebo Applied
Description: The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
Study: NCT00850330

Intervention type: OTHER
Intervention: on line software to detect DI early on
Description: Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
Study: NCT04605250

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory variability before and after surgery
Description: The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
Study: NCT03113344

Intervention type: DRUG
Intervention: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Study: NCT02712203

Intervention type: BIOLOGICAL
Intervention: MMR vaccine / MMRV vaccine
Description: Subcutaneous injection, two doses

Intervention type: BIOLOGICAL
Intervention: MMR vaccine / MMRV vaccine
Description: Subcutaneous injection, two doses

Intervention type: BIOLOGICAL
Intervention: MMR vaccine / MMRV vaccine
Description: Subcutaneous injection, two doses

Intervention type: BIOLOGICAL
Intervention: MMR vaccine / MMRV vaccine
Description: Subcutaneous injection, two doses
Study: NCT00553254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT04164901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Vorasidenib oral film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo oral tablets
Study: NCT01190527

Intervention type: RADIATION
Group type: OTHER
Intervention: FDG-PET
Description: This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
Study: NCT01942369

Intervention type: DRUG
Intervention: Triptorelin Acetate 3.75mg intramuscular injection
Description: Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks.
Study: NCT03277599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV patient-controlled analgesia (PCA) tramadol
Description: Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV patient-controlled analgesia (PCA) tramadol
Description: Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided superficial cervical plexus block
Description: ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Great Auricular nerve block
Description: ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
Study: NCT04957589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet
Description: A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
Study: NCT04278820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3526
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3526
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3526
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match TQA3526
Description: Tablet(s) administered orally once daily
Study: NCT01193270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
Study: NCT03748550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
Study: NCT06637202

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative radiotherapy
Description: 50 Gy in 25 fractions
Study: NCT04278820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match TQA3526
Description: Tablet(s) administered orally once daily
Study: NCT06562829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality technology
Description: Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality technology
Description: Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different timing of lidocaine injection
Description: Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
Study: NCT06638684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
Study: NCT02853136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine
Study: NCT01193270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water in volume equal to that of the comparator drug
Study: NCT03254979

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle prescription
Description: 3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle prescription
Description: 3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits.
Study: NCT01180621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral
Description: 0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
Study: NCT01011335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent rAT
Description: 10, 25, 50 or 100 μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent rLukS-PV
Description: 10, 25, 50 or 100 μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLukS-PV / rAT
Description: 10, 25 or 50 μg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with adjuvant
Description: Placebo with adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline
Study: NCT00282581

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVA Smallpox Vaccine
Description: 0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
Study: NCT02685696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis O Retractor
Description: A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Retractor
Description: The traditional self-retaining metal Collins Caesarean Wound Retractor.
Study: NCT02824185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)
Description: A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
Study: NCT03815240

Intervention type: OTHER
Group type: OTHER
Intervention: No dressing
Description: no dressing at sacrum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Border Sacrum
Description: adhesive sacrum dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALLEVYN Life Sacrum
Description: adhesive sacrum dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optifoam® Gentle Sacrum
Description: adhesive sacrum dressing
Study: NCT03257215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stoss vitamin D
Description: A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily vitamin D
Description: Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stoss placebo
Description: A single 1.5 mL dose administered on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stoss placebo
Description: A single 1.5 mL dose administered on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily placebo
Description: A once daily 0.2 mL dose administered from Day 1 to 90

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily placebo
Description: A once daily 0.2 mL dose administered from Day 1 to 90
Study: NCT03700827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: High-intensity Resistance Training Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic Interval Training Group
Study: NCT01953887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: oral
Study: NCT03877341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral fusion
Description: Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior lumbar interbody fusion
Description: Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
Study: NCT04889391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Danicopan
Description: Liquid-filled capsules.
Study: NCT02096367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinematic gait analysis in lower limb

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of static posture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait on treadmill
Description: Treadmill during 2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle vibration stimulation
Description: Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
Study: NCT03160586

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stuttering severity instrument-3
Description: To measure of degree of stuttering in child

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Child Behavior Checklist for age 4-18
Description: To measure of percent of anxiety in child by ask parents about his or her behaviour

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Child Behavior Checklist for age 4-18
Description: To measure of percent of anxiety in child by ask parents about his or her behaviour
Study: NCT02039063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 15 mg/kg
Study: NCT03278509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).